| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 28, 2022
-- Nexpowder™* provides gastroenterologists improved visibility, controls upper gastrointestinal (GI) bleeding effectively and with ease1,2,3 --
-- Nexpowder™* endoscopic hemostasis system showed a lower rebleeding rate and has nearly double the adhesive force of other hemostatic sprays2,3 --
-
Sep 18, 2022
TCT 2022: Late-breaking data from Intrepid™ Pilot Study 3-year follow-up & 1-year follow-up from Transfemoral EFS study demonstrate promising valve performance Medtronic today announced new data...
-
Sep 16, 2022
TCT 2022: Pathological Findings Confirm Importance of Early Detection and Treatment of Thrombus on Valve Leaflets Medtronic today announced findings from its Pathological Study of Hypo-Attenuated...
-
Sep 16, 2022
TCT 2022: Medtronic Unveils Latest Transcatheter Aortic Valve Replacement Data in Late-Breaking Clinical Science and Presentations
-
May 17, 2022
Mid-term results of Optimize PRO clinical study reinforces benefits of predictability and control using cusp overlap technique
-
May 2, 2022
EXPAND TAVR II Pivotal Trial evaluating the Evolut™ TAVR platform in a new patient population
-
Apr 27, 2022
Medtronic, the global leader in medical technology, today announced new randomized controlled data demonstrating the sustained and superior performance of IN.PACT AV drug coated balloon (DCB)...
-
Apr 4, 2022
ACC.22: Late-breaking data show CoreValve™ and Evolut™ is the only platform to out-perform surgery in valve durability at five years